Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Considers Ban On Anti-Obesity Drugs With Rimonabant

This article was originally published in PharmAsia News

Executive Summary

Indian drug regulators are considering a ban on certain anti-obesity drugs in the country, those containing rimonabant, which has been linked to suicidal tendencies. Ranbaxy Laboratories, Sun Pharma, Zydus Cadila are among generics makers of drugs containing rimonabant, first used by Sanofi Aventis. India's Drug Technical Advisory Board has urged the nation's health ministry to ban such drugs outright. The head of the board noted the drug has demonstrated serious psychiatric effects, leading most other nations to ban it. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel